What one share of Actuate Therapeutics holds
We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (“GSK-3”).
Actuate Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.89 |
|---|---|
| Cash and investments | $0.18 |
| Book value | $0.04 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$17.24 | — | — | — | −$58.92 |
| 2024 | — | −$3.26 | — | — | — | — |
| 2025 | — | −$1.06 | — | — | — | $0.34 |
Common questions about Actuate Therapeutics
How much does one share of Actuate Therapeutics earn?
Over the last 12 months, Actuate Therapeutics lost $0.89 for each share.
Does Actuate Therapeutics pay a dividend?
Actuate Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Actuate Therapeutics’s book value per share?
Actuate Therapeutics’s book value is $0.04 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Actuate Therapeutics have?
Each share of Actuate Therapeutics has $0.18 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.